Literature DB >> 21256602

Neuroprotective therapeutics for Alzheimer's disease: progress and prospects.

Alan M Palmer1.   

Abstract

The number of people with Alzheimer's disease (AD) has never been greater and is set to increase substantially in the decades ahead as the proportion of the population aged 65 years or more rises sharply. There is therefore an urgent need for safe and effective pharmacotherapy to help combat the corresponding and substantial increase in disease burden. Increased understanding of disease aetiology and pathophysiology, particularly in relation to the loss of vulnerable neurons and the formation of plaques and tangles, has increased hope for medications that can slow (or perhaps even halt) the course of the disease. In this article I review the neurobiological basis of AD, current progress towards neuroprotective therapeutics, and prospects for the future.
Copyright © 2010 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21256602     DOI: 10.1016/j.tips.2010.12.007

Source DB:  PubMed          Journal:  Trends Pharmacol Sci        ISSN: 0165-6147            Impact factor:   14.819


  30 in total

Review 1.  Turning on the Light Within: Subcortical Nuclei of the Isodentritic Core and their Role in Alzheimer's Disease Pathogenesis.

Authors:  Panos Theofilas; Sara Dunlop; Helmut Heinsen; Lea Tenenholz Grinberg
Journal:  J Alzheimers Dis       Date:  2015       Impact factor: 4.472

2.  Syntheses, neural protective activities, and inhibition of glycogen synthase kinase-3β of substituted quinolines.

Authors:  Jianyu Lu; Izumi Maezawa; Sahani Weerasekara; Ramazan Erenler; Tuyen D T Nguyen; James Nguyen; Luxi Z Swisher; Jun Li; Lee-Way Jin; Alok Ranjan; Sanjay K Srivastava; Duy H Hua
Journal:  Bioorg Med Chem Lett       Date:  2014-06-04       Impact factor: 2.823

Review 3.  Is amyloid binding alcohol dehydrogenase a drug target for treating Alzheimer's disease?

Authors:  Eva Borger; Laura Aitken; Heng Du; Wenshen Zhang; Frank J Gunn-Moore; Shirley Shi Du Yan
Journal:  Curr Alzheimer Res       Date:  2013-01       Impact factor: 3.498

4.  Multi-modal latent space inducing ensemble SVM classifier for early dementia diagnosis with neuroimaging data.

Authors:  Tao Zhou; Kim-Han Thung; Mingxia Liu; Feng Shi; Changqing Zhang; Dinggang Shen
Journal:  Med Image Anal       Date:  2019-12-28       Impact factor: 8.545

Review 5.  Neuroimaging results impose new views on Alzheimer's disease--the role of amyloid revised.

Authors:  Anders M Fjell; Kristine B Walhovd
Journal:  Mol Neurobiol       Date:  2011-12-27       Impact factor: 5.590

Review 6.  Intracellular cAMP Sensor EPAC: Physiology, Pathophysiology, and Therapeutics Development.

Authors:  William G Robichaux; Xiaodong Cheng
Journal:  Physiol Rev       Date:  2018-04-01       Impact factor: 37.312

Review 7.  Hypoxia inducible factor-1 as a target for neurodegenerative diseases.

Authors:  Z Zhang; J Yan; Y Chang; S ShiDu Yan; H Shi
Journal:  Curr Med Chem       Date:  2011       Impact factor: 4.530

Review 8.  Structural and mechanistic commonalities of amyloid-β and the prion protein.

Authors:  Bianca Da Costa Dias; Katarina Jovanovic; Danielle Gonsalves; Stefan F T Weiss
Journal:  Prion       Date:  2011-07-01       Impact factor: 3.931

9.  Evaluation of nicotine and cotinine analogs as potential neuroprotective agents for Alzheimer's disease.

Authors:  Jie Gao; Bao-Ling Adam; Alvin V Terry
Journal:  Bioorg Med Chem Lett       Date:  2014-02-14       Impact factor: 2.823

10.  5-HT4 receptors constitutively promote the non-amyloidogenic pathway of APP cleavage and interact with ADAM10.

Authors:  Maud Cochet; Romain Donneger; Elisabeth Cassier; Florence Gaven; Stefan F Lichtenthaler; Philippe Marin; Joël Bockaert; Aline Dumuis; Sylvie Claeysen
Journal:  ACS Chem Neurosci       Date:  2012-10-13       Impact factor: 4.418

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.